» Articles » PMID: 18979209

DNA Alkylation Products Formed by 1-(2-chloroethyl)-1-nitrosourea As Molecular Dosimeters of Therapeutic Response

Overview
Journal J Neurooncol
Publisher Springer
Date 2008 Nov 4
PMID 18979209
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

This study has investigated if individual DNA adducts formed in human glioma cells treated with (3)H-1-(2-chloroethyl)-1-nitrosourea ((3)H-CNU) could be used as molecular dosimeters of response after CENU treatment. The levels of individual DNA alkylation products were compared with the induction of cytotoxicity in six human glioma cell lines after treatment with (3)H-CNU. The levels of seven DNA adducts N7-(2-hydroxyethyl)guanine, (N7-HOEtG); N7-(2-chloroethyl)guanine, (N7-ClEtG); 1,2-[diguan-7-yl]-ethane, (N7-bis-G); N1-(2-hydroxyethyl)-2-deoxyguanosine, N1-HOEtdG; 1-[N1-2-deoxyguanosinyl], 2-[N3-2-deoxycytidyl]-ethane, dG-dC; O(6)-(2-hydroxyethyl)-2-deoxyguanosine, O(6)-HOEtdG and phosphotriesters (PTE), were quantified in each of the cell lines following treatment with (3)H-CNU. The levels of N7-HOEtG, N7-ClEtG; O(6)-HOEtdG and PTE were not significantly different in the glioma lines and their levels were not associated with the induction of cytotoxicity by CNU treatment. The levels of N7-bis-G, N1-HOEtdG and dG-dC crosslink were significantly lower in both SF-188 and SF-763 cell lines compared to their levels in U87MG, U251MG and SF-126. There was a significant correlation between CNU LD(10) values and with the levels of levels of N7-bis-G and N1-HOEtdG (R = -0.91, P = 0.01) and dG-dC crosslink (R = -0.94, P = 0.005) in the glioma cell lines. Pretreatment of SF-188 cells with varying concentrations of MNU prior to CNU treatment resulted in no change in the levels of N7-HOEtG, N7-ClEtG; O(6)-HOEtdG and PTE and a dose dependent increase in the levels of N7-bis-G, N1-HOEtdG and dG-dC crosslink. Taken together, these results suggest that the levels of the N7-bis-G, N1-HOEtdG and dG-dC crosslink could be used as molecular dosimeters of therapeutic response following treatment with BCNU or related CENU.

Citing Articles

Energy Blocker Lonidamine Reverses Nimustine Resistance in Human Glioblastoma Cells through Energy Blockade, Redox Homeostasis Disruption, and -Methylguanine-DNA Methyltransferase Downregulation: and Validation.

Huang Y, Wang P, Fan T, Zhang N, Zhao L, Zhong R ACS Pharmacol Transl Sci. 2024; 7(5):1518-1532.

PMID: 38751635 PMC: 11092191. DOI: 10.1021/acsptsci.4c00085.


Reductive Activity and Mechanism of Hypoxia- Targeted AGT Inhibitors: An Experimental and Theoretical Investigation.

Xiao W, Sun G, Fan T, Liu J, Zhang N, Zhao L Int J Mol Sci. 2019; 20(24).

PMID: 31847200 PMC: 6941096. DOI: 10.3390/ijms20246308.


Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells.

Chakkath T, Lavergne S, Fan T, Bunick D, Dirikolu L Vet Sci. 2017; 2(2):52-68.

PMID: 29061931 PMC: 5644621. DOI: 10.3390/vetsci2020052.


Influence of the Expression Level of O6-Alkylguanine-DNA Alkyltransferase on the Formation of DNA Interstrand Crosslinks Induced by Chloroethylnitrosoureas in Cells: A Quantitation Using High-Performance Liquid Chromatography-Mass Spectrometry.

Li L, Li S, Sun G, Peng R, Zhao L, Zhong R PLoS One. 2015; 10(3):e0121225.

PMID: 25799182 PMC: 4370500. DOI: 10.1371/journal.pone.0121225.

References
1.
Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M . Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10):2596-606. DOI: 10.1093/brain/awm204. View

2.
Groothuis D . The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2001; 2(1):45-59. PMC: 1920694. DOI: 10.1093/neuonc/2.1.45. View

3.
Guha A, Mukherjee J . Advances in the biology of astrocytomas. Curr Opin Neurol. 2004; 17(6):655-62. DOI: 10.1097/00019052-200412000-00004. View

4.
Levin V, Uhm J, Jaeckle K, Choucair A, Flynn P, Yung WKA . Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000; 6(10):3878-84. View

5.
Curran Jr W, Scott C, Horton J, Nelson J, Weinstein A, Fischbach A . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85(9):704-10. DOI: 10.1093/jnci/85.9.704. View